GFP/Luc Reporter Cell Line - HCC4006

The HCC4006 cell line is a well-established human model of non-small cell lung cancer (NSCLC), originally isolated from the pleural effusion of a patient with metastatic lung adenocarcinoma. It is highly valued in pulmonary oncology for harboring an endogenous activating deletion in exon 19 of the epidermal growth factor receptor (EGFR) gene, making it a critical preclinical tool for studying EGFR-driven malignancies. The GFP/Luc Reporter Cell Line - HCC4006 is a sophisticated, stably transfected derivative engineered to simultaneously co-express both Green Fluorescent Protein (GFP) and firefly luciferase (Luc). This robust dual-labeling construct ensures consistent, high-level expression of both functional reporter genes across sequential in vitro passages. Crucially, this genetic integration is achieved while rigorously preserving the fundamental biological properties, the unique mutational profile, and the intrinsic tumorigenic capacity of the original parental HCC4006 cells.

The incorporation of this dual-reporter system significantly expands the analytical capabilities of the HCC4006 model for translational respiratory research. In vitro, the distinct GFP tag enables researchers to easily monitor cellular morphology, quantify proliferation rates, and isolate specific subpopulations using standard fluorescence microscopy and flow cytometry. For in vivo studies, the strong luciferase expression provides the optimal foundation for non-invasive, longitudinal tracking of primary tumor progression and metastatic spread through bioluminescence imaging (BLI). Because it is a human-derived cell line, the HCC4006-GFP/Luc model is typically engrafted into immunocompromised mice (such as athymic nude or NSG strains) to establish localized subcutaneous xenografts or orthotopic lung models. This specialized reporter line serves as an indispensable platform for evaluating the therapeutic efficacy of targeted pharmacological compounds, particularly EGFR tyrosine kinase inhibitors (TKIs), and for studying mechanisms of acquired drug resistance. By facilitating the real-time, accurate quantification of tumor burden in living subjects, it greatly accelerates preclinical discoveries in precision lung oncology.